

# Guide a Systematic Approach to Manage Acute Hyperkalemia

**Does patiromer (*Veltassa*) or sodium zirconium cyclosilicate (*Lokelma*) have a role in treating acute hyperkalemia?**

Often, yes...alongside other measures.

Both meds work similarly to sodium polystyrene sulfonate (*Kayexalate*)...by binding potassium in the GI tract.

Limited data suggest that potassium lowering is roughly comparable within 24 hours of a single dose of any of these binders.

And cost is similar...about \$30/dose for patiromer 8.4 g, sodium zirconium cyclosilicate 10 g, or sodium polystyrene sulfonate 15 g.

But sodium polystyrene sulfonate is poorly tolerated due to bad taste and constipation...plus it carries concerns about bowel necrosis.

If a binder is needed, generally lean toward sodium zirconium cyclosilicate. It starts working in about 1 hour...versus 2 hours for sodium polystyrene sulfonate...or 4 hours for patiromer.

But ensure that binders aren't used alone for acute life-threatening hyperkalemia...guide a systematic approach.

**Stabilize the heart.** Start with IV calcium in patients with potassium 6.5 mEq/L or higher...or ECG changes at any elevated level.

**Shift potassium into cells.** Think of regular insulin 10 units plus 25 grams of 50% dextrose...given IV...as the gold standard.

But hypoglycemia is common. Consider strategies to reduce risk.

For example, add dextrose 10% at 50 ml/hr for 5 hours after the insulin and dextrose dose for patients at increased risk...such as if baseline blood glucose is less than 125 mg/dL.

And monitor closely...such as glucose checks hourly for 6 hours.

Consider nebulized albuterol 10 to 20 mg...about 4 times more than the standard neb dose. Be aware, albuterol may not be effective for some patients...such as those on a nonselective beta-blocker.

Hold off on sodium bicarbonate unless the patient has metabolic acidosis...since overall data are mixed.

**Remove potassium.** Consider adding a binder...AFTER acute meds.

And try loop diuretics...but expect patients with severe kidney dysfunction to need hemodialysis.

**Review meds.** Look for culprits that may raise potassium on the med list...such as an ACEI, ARB or spironolactone, NSAIDs, or trimethoprim. And don't forget to ask about dietary supplements.

Bookmark our resource, *Management of Hyperkalemia*, for more on acute and chronic treatment.

## Key References:

- Rydell A, Thackrey C, Molki M, Mullins BP. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia. *Ann Pharmacother.* 2023 Nov 12:10600280231209968.
- Sullivan E, Ruegger M, Dunne I, et al. Comparison of effectiveness and safety of sodium polystyrene sulfonate

Cite this document as follows: Article, Guide a Systematic Approach to Manage Acute Hyperkalemia, Hospital Pharmacist's Letter, April 2024

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email [sales@trchealthcare.com](mailto:sales@trchealthcare.com).

© 2024 Therapeutic Research Center (TRC). TRC and Hospital Pharmacist's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.

and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients. *Am J Health Syst Pharm.* 2023 Sep 7;80(18):1238-1246.

- Joyce O, Corpman M. Comparison of Sodium Zirconium Cyclosilicate to Sodium Polystyrene Sulfonate in the Inpatient Management of Acute Hyperkalemia. *J Pharm Pract.* 2023 May 30:8971900231176462.
- Di Palo KE, Sinnott MJ, Goriacko P. Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting. *JAMA Netw Open.* 2022 Jan 4;5(1):e2145236.
- UK Kidney Association. Clinical Practice Guidelines:Treatment of Acute Hyperkalaemia in Adults. October 2023. [https://ukkidney.org/sites/renal.org/files/FINAL%20VERSION%20-%20UKKA%20CLINICAL%20PRACTICE%20GUIDELINE%20-%20MANAGEMENT%20OF%20HYPERKALAEMIA%20IN%20ADULTS%20-%2020191223\\_0.pdf](https://ukkidney.org/sites/renal.org/files/FINAL%20VERSION%20-%20UKKA%20CLINICAL%20PRACTICE%20GUIDELINE%20-%20MANAGEMENT%20OF%20HYPERKALAEMIA%20IN%20ADULTS%20-%2020191223_0.pdf) (Accessed Jan 25, 2024).
- Lindner G, Burdmann EA, Clase CM, et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. *Eur J Emerg Med.* 2020 Oct;27(5):329-337.
- Medication pricing by Elsevier, accessed Mar 2024.

Hospital Pharmacist's Letter. April 2024, No. 400417

Cite this document as follows: Article, Guide a Systematic Approach to Manage Acute Hyperkalemia, Hospital Pharmacist's Letter, April 2024

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email [sales@trchealthcare.com](mailto:sales@trchealthcare.com).

© 2024 Therapeutic Research Center (TRC). TRC and Hospital Pharmacist's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.